Recent Advances with Liposomes as Drug Carriers

Advanced Biomaterials and Biodevices

Volumn 9781118773635, Issue , 2014, Pages 79-119

  Sriraman, Shravan Kumar ^a   Torchilin, Vladimir P ^a  

^a NORTHEASTERN UNIVERSITY   (United States)

Author keywords

Active targeting; Antibody targeted liposomes; Drug carriers; Drug delivery; Dual targeted liposomes; Liposomes; Multifunctional liposomes; Passive targeting

Indexed keywords

COATINGS; CONTROLLED DRUG DELIVERY; PHOSPHOLIPIDS; TARGETED DRUG DELIVERY;

ACTIVE TARGETING; ANTIBODY-TARGETED; ANTIBODY-TARGETED LIPOSOME; BILAYERED; BIOLOGICAL COMPOUNDS; DRUG CARRIER; DUAL-TARGETED LIPOSOME; MULTIFUNCTIONAL LIPOSOME; PASSIVE TARGETING; PHOSPHOLIPID VESICLES;

LIPOSOMES;

EID: 84927794833     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781118774052.ch3     Document Type: Chapter

References (293)

1. Bangham, A., M. Standish, and J. Watkins, Diffusion of univalent ions across the lamellae of swollen phospholipids. Journal of Molecular Biology, 1965. 13(1): p. 238-IN27.
2. Gregoriadis, G. and B. Ryman, Liposomes as carriers of enzymes or drugs: a new approach to the treatment of storage diseases. Biochemical Journal, 1971. 124(5): p. 58P.
3. Zalba, S. and M. J. Garrido, Liposomes, a promising strategy for clinical application of platinum derivatives. Expert Opin Drug Deliv, 2013. 10(6): p. 829-44.
4. Gregoriadis, G., Liposome Technology. Vol. I. 1993: CRC Press.
5. Banerjee, R., Liposomes: applications in medicine. Journal of Biomaterials Applications, 2001. 16(1): p. 3-21.
6. Torchilin, V. P., Recent advances with liposomes as pharmaceutical carriers. Nature Reviews Drug Discovery, 2005. 4(2): p. 145-160.
7. Sawant, R. R. and V. P. Torchilin, Challenges in development of targeted liposomal therapeutics. AAPS J, 2012. 14(2): p. 303-315.
8. Maeda, H., et al., Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. Journal of Controlled Release, 2000. 65(1): p. 271-284.
9. Hu, D., et al., Pharmacokinetic profile of liposome bupivacaine injection following a single administration at the surgical site. Clin Drug Investig, 2013. 33(2): p. 109-15.
10. Ismail, M. F., A. N. Elmeshad, and N. A. Salem, Potential therapeutic effect of nanobased formulation of rivastigmine on rat model of Alzheimer's disease. Int J Nanomedicine, 2013. 8: p. 393-406.
11. Kaszas, N., et al., Ciprofloxacin encapsulation into giant unilamellar vesicles: membrane binding and release. J Pharm Sci, 2013. 102(2): p. 694-705.
12. Liu, X., et al., Clarithromycin-loaded liposomes offering high drug loading and less irritation. Int J Pharm, 2013. 443(1-2): p. 318-27.
13. Kim, B., et al., Antitumor effect of a newly synthesized celecoxib derivative encapsulated in liposome. Journal of Pharmaceutical Investigation, 2013. 43(2): p. 101-106.
14. Lalanne, M., et al., Liposomal formulation of a glycerolipidic prodrug for lymphatic delivery of didanosine via oral route. Int J Pharm, 2007. 344(1-2): p. 62-70.
15. Wagner, E. J., L. Krugner-Higby, and T. D. Heath, Liposome dependent delivery of S-adenosyl methionine to cells by liposomes: a potential treatment for liver disease. J Pharm Sci, 2009. 98(2): p. 573-82.
16. Bornmann, C., et al., A new liposomal formulation of Gemcitabine is active in an orthotopic mouse model of pancreatic cancer accessible to bioluminescence imaging. Cancer Chemother Pharmacol, 2008. 61(3): p. 395-405.
17. Chen, C., et al., An in vitro study of liposomal curcumin: stability, toxicity and biological activity in human lymphocytes and Epstein-Barr virus-transformed human B-cells. Int J Pharm, 2009. 366(1-2): p. 133-9.
18. Orr, W. S., et al., Liposome-encapsulated curcumin suppresses neuroblastoma growth through nuclear factor-kappa B inhibition. Surgery, 2012. 151(5): p. 736-44.
19. Wang, D., et al., Liposome-encapsulated curcumin suppresses growth of head and neck squamous cell carcinoma in vitro and in xenografts through the inhibition of nuclear factor kappaB by an AKT-independent pathway. Clin Cancer Res, 2008. 14(19): p. 6228-36.
20. Li, S., et al., In-vitro and in-vivo evaluation of austocystin D liposomes. J Pharm Pharmacol, 2013. 65(3): p. 355-62.
21. O'Brien, S., et al., High-dose vincristine sulfate liposome injection for advanced, relapsed, and refractory adult Philadelphia chromosome-negative acute lymphoblastic leukemia. J Clin Oncol, 2013. 31(6): p. 676-83.
22. Gupta, V., et al., Liposomal fasudil, a rho-kinase inhibitor, for prolonged pulmonary preferential vasodilation in pulmonary arterial hypertension. J Control Release, 2013. 167(2): p. 189-99.
23. Chithrani, D. B., et al., Cellular uptake and transport of gold nanoparticles incorporated in a liposomal carrier. Nanomedicine, 2010. 6(1): p. 161-9.
24. Sandhya, K. V., G. S. Devi, and S. T. Mathew, Liposomal formulations of serratiopeptidase: In vitro studies using PAMPA and caco-2 models. Mol Pharm, 2008. 5(1): p. 92-97.
25. Zeevalk, G. D., L. P. Bernard, and F. T. Guilford, Liposomal-glutathione provides maintenance of intracellular glutathione and neuroprotection in mesencephalic neuronal cells. Neurochem Res, 2010. 35(10): p. 1575-87.
26. Alves, J. B., et al., Local delivery of EGF-liposome mediated bone modeling in orthodontic tooth movement by increasing RANKL expression. Life Sci, 2009. 85(19-20): p. 693-9.
27. Bhansali, S. G., S. V. Balu-Iyer, and M. E. Morris, Influence of route of administration and liposomal encapsulation on blood and lymph node exposure to the protein VEGF-C156S. J Pharm Sci, 2012. 101(2): p. 852-9.
28. Dvoriantchikova, G., et al., Liposome-delivered ATP effectively protects the retina against ischemia-reperfusion injury. Mol Vis, 2010. 16: p. 2882-90.
29. Martinez-Lostao, L., et al., Liposome-bound APO2L/TRAIL is an effective treatment in a rabbit model of rheumatoid arthritis. Arthritis Rheum, 2010. 62(8): p. 2272-82.
30. Villares, G. J., et al., Targeting melanoma growth and metastasis with systemic delivery of liposome-incorporated protease-activated receptor-1 small interfering RNA. Cancer Res, 2008. 68(21): p. 9078-86.
31. Hak, S., et al., A high relaxivity Gd(III)DOTA-DSPE-based liposomal contrast agent for magnetic resonance imaging. Eur J Pharm Biopharm, 2009. 72(2): p. 397-404.
32. Franz-Montan, M., et al., Liposomal-benzocaine gel formulation: correlation between in vitro assays and in vivo topical anesthesia in volunteers. J Liposome Res, 2013. 23(1): p. 54-60.
33. Singh, H. P., et al., Elastic liposomal formulation for sustained delivery of colchicine: in vitro characterization and in vivo evaluation of anti-gout activity. AAPS J, 2009. 11(1): p. 54-64.
34. Hajos, F., et al., Inhalable liposomal formulation for vasoactive intestinal peptide. Int J Pharm, 2008. 357(1-2): p. 286-94.
35. Yang, W., et al., Survivin downregulation by siRNA/cationic liposome complex radiosensitises human hepatoma cells in vitro and in vivo. Int J Radiat Biol, 2010. 86(6): p. 445-57.
36. Li, C., et al., RNA interference targeting human FAK and EGFR suppresses human non-small-cell lung cancer xenograft growth in nude mice. Cancer Gene Ther, 2013. 20(2): p. 101-8.
37. Commander, N. J., et al., Liposomal delivery of p-ialB and p-omp25 DNA vaccines improves immunogenicity but fails to provide full protection against B. melitensis challenge. Genet Vaccines Ther, 2010. 8: p. 5.
38. Ito, Y., et al., Evaluation of proinflammatory cytokine production and liver injury induced by plasmid DNA/cationic liposome complexes with various mixing ratios in mice. Eur J Pharm Biopharm, 2009. 71(2): p. 303-9.
39. Park, J., et al., The effect on bone regeneration of a liposomal vector to deliver BMP-2 gene to bone grafts in peri-implant bone defects. Biomaterials, 2007. 28(17): p. 2772-82.
40. Qiao, W. and M. Zhou, Hydroxyl-modified cationic lipids with a carbamate linkage as gene delivery vehicles. European Journal of Lipid Science and Technology, 2013. 115(5): p. 483-489.
41. Beisner, J., et al., Efficient telomerase inhibition in human non-small cell lung cancer cells by liposomal delivery of 2'-O-methyl-RNA. J Pharm Sci, 2009. 98(5): p. 1765-74.
42. De Rosa, G., et al., Novel cationic liposome formulation for the delivery of an oligonucleotide decoy to NF-kappaB into activated macrophages. Eur J Pharm Biopharm, 2008. 70(1): p. 7-18.
43. Kashyap, M., et al., Down-Regulation of Nerve Growth Factor Expression in the Bladder by Antisense Oligonucleotides as New Treatment for Overactive Bladder. J Urol, 2013.
44. Aleku, M., et al., Atu027, a liposomal small interfering RNA formulation targeting protein kinase N3, inhibits cancer progression. Cancer Res, 2008. 68(23): p. 9788-98.
45. Dass, C. R., et al., Downregulation of c-jun results in apoptosis-mediated anti-osteosarcoma activity in an orthotopic model. Cancer Biol Ther, 2008. 7(7): p. 1033-6.
46. Ye, L., et al., Angiomyogenesis using liposome based vascular endothelial growth factor-165 transfection with skeletal myoblast for cardiac repair. Biomaterials, 2008. 29(13): p. 2125-37.
47. Gross, N., et al., Choroidal neovascularization reduced by targeted drug delivery with cationic liposome-encapsulated paclitaxel or targeted photodynamic therapy with verteporfin encapsulated in cationic liposomes. Mol Vis, 2013. 19: p. 54-61.
48. Henriksen-Lacey, M., et al., Liposomal cationic charge and antigen adsorption are important properties for the efficient deposition of antigen at the injection site and ability of the vaccine to induce a CMI response. J Control Release, 2010. 145(2): p. 102-8.
49. Torchilinl, V. and M. Papisov, Why do polyethylene glycol-coated liposomes circulate so long?: Molecular mechanism of liposome steric protection with polyethylene glycol: Role of polymer chain flexibility. J Liposome Res, 1994. 4(1): p. 725-739.
50. Er, Y., et al., The encapsulation and release of guanosine from PEGylated liposomes. J Liposome Res, 2009. 19(1): p. 29-36.
51. Gabizon, A., et al., Therapeutic efficacy of a lipid-based prodrug of mitomycin C in pegylated liposomes: studies with human gastro-entero-pancreatic ectopic tumor models. J Control Release, 2012. 160(2): p. 245-53.
52. Grenader, T., et al., Malignant epithelioid hemangioendothelioma of the liver successfully treated with pegylated liposomal doxorubicin. J Clin Oncol, 2011. 29(25): p. e722-4.
53. Jung, S. H., et al., Polyethylene glycol-complexed cationic liposome for enhanced cellular uptake and anticancer activity. Int J Pharm, 2009. 382(1-2): p. 254-61.
54. Kajiwara, E., et al., Long-circulating liposome-encapsulated ganciclovir enhances the efficacy of HSV-TK suicide gene therapy. J Control Release, 2007. 120(1-2): p. 104-10.
55. Yang, T., et al., Enhanced solubility and stability of PEGylated liposomal paclitaxel: in vitro and in vivo evaluation. Int J Pharm, 2007. 338(1-2): p. 317-26.
56. Yang, X., et al., A novel liposomal formulation of flavopiridol. Int J Pharm, 2009. 365(1-2): p. 170-4.
57. Zamboni, W. C., et al., Plasma, tumor, and tissue disposition of STEALTH liposomal CKD-602 (S-CKD602) and nonliposomal CKD-602 in mice bearing A375 human melanoma xenografts. Clin Cancer Res, 2007. 13(23): p. 7217-23.
58. Seetharamu, N., et al., Phase II study of liposomal cisplatin (SPI-77) in platinum-sensitive recurrences of ovarian cancer. Anticancer Res, 2010. 30(2): p. 541-5.
59. Tippayamontri, T., et al., Cellular uptake and cytoplasm / DNA distribution of cisplatin and oxaliplatin and their liposomal formulation in human colorectal cancer cell HCT116. Invest New Drugs, 2011. 29(6): p. 1321-7.
60. Hwang, T., et al., Anticancer Drug-Phospholipid Conjugate for Enhancement of Intracellular Drug Delivery. Macromol Symp, 2007. 249-250(1): p. 109-115.
61. Luo, H., et al., Liposomal honokiol, a promising agent for treatment of cisplatin-resistant human ovarian cancer. J Cancer Res Clin Oncol, 2008. 134(9): p. 937-45.
62. Banciu, M., et al., Antitumor activity and tumor localization of liposomal glucocorticoids in B16 melanoma-bearing mice. J Control Release, 2008. 127(2): p. 131-6.
63. Zolnik, B. S., et al., Rapid distribution of liposomal short-chain ceramide in vitro and in vivo. Drug Metab Dispos, 2008. 36(8): p. 1709-15.
64. Caraglia, M., et al., Stealth liposomes encapsulating zoledronic acid: a new opportunity to treat neuropathic pain. Mol Pharm, 2013. 10(3): p. 1111-8.
65. Gaspar, M. M., et al., Enzymosomes with surface-exposed superoxide dismutase: in vivo behaviour and therapeutic activity in a model of adjuvant arthritis. J Control Release, 2007. 117(2): p. 186-95.
66. Ishii, T., et al., Amelioration of cerebral ischemia-reperfusion injury based on liposomal drug delivery system with asialo-erythropoietin. J Control Release, 2012. 160(1): p. 81-7.
67. Kawaguchi, A. T., et al., Liposome-encapsulated hemoglobin ameliorates ischemic stroke in nonhuman primates: an acute study. J Pharmacol Exp Ther, 2010. 332(2): p. 429-36.
68. Verma, D. D., et al., Protective effect of coenzyme Q10-loaded liposomes on the myocardium in rabbits with an acute experimental myocardial infarction. Pharm Res, 2007. 24(11): p. 2131-7.
69. Xing, C., et al., Delivering minocycline into brain endothelial cells with liposome-based technology. J Cereb Blood Flow Metab, 2012. 32(6): p. 983-8.
70. Linker, R. A., et al., Liposomal glucocorticosteroids in treatment of chronic autoimmune demyelination: long-term protective effects and enhanced efficacy of methylprednisolone formulations. Exp Neurol, 2008. 211(2): p. 397-406.
71. Pan, J., et al., Enhanced efficacy of recombinant FVIII in noncovalent complex with PEGylated liposome in hemophilia A mice. Blood, 2009. 114(13): p. 2802-11.
72. Stark, B., et al., Liposomal vasoactive intestinal peptide for lung application: protection from proteolytic degradation. Eur J Pharm Biopharm, 2008. 70(1): p. 153-64.
73. van Rooy, I., et al., Preparation and characterization of liposomal formulations of neurotensin-degrading enzyme inhibitors. Int J Pharm, 2011. 416(2): p. 448-52.
74. Garcia, L., et al., Serum-resistant lipopolyplexes for gene delivery to liver tumour cells. Eur J Pharm Biopharm, 2007. 67(1): p. 58-66.
75. Ho, E. A., et al., Characterization of long-circulating cationic nanoparticle formulations consisting of a two-stage PEGylation step for the delivery of siRNA in a breast cancer tumor model. J Pharm Sci, 2013. 102(1): p. 227-36.
76. Komano, Y., et al., Arthritic joint-targeting small interfering RNA-encapsulated liposome: implication for treatment strategy for rheumatoid arthritis. J Pharmacol Exp Ther, 2012. 340(1): p. 109-13.
77. Lee, J. B., et al., Lipid nanoparticle siRNA systems for silencing the androgen receptor in human prostate cancer in vivo. Int J Cancer, 2012. 131(5): p. E781-90.
78. Tagami, T., et al., Anti-angiogenic therapy via cationic liposome-mediated systemic siRNA delivery. Int J Pharm, 2012. 422(1-2): p. 280-9.
79. Tagami, T., et al., Anti-PEG IgM production by siRNA encapsulated in a PEGylated lipid nanocarrier is dependent on the sequence of the siRNA. J Control Release, 2011. 151(2): p. 149-54.
80. Xie, J., et al., An anionic long-circulating liposome that improves radioiodinated antisense oligonucleotide delivery in vitro and in vivo. Advances in Polymer Technology, 2012. 31(1): p. 20-28.
81. Bai, J., et al., Impact of PEGylation on biodistribution and tumor accumulation of Lipid-Mu peptide-DNA. J Liposome Res, 2013. 23(1): p. 1-10.
82. Romberg, B., et al., Pharmacokinetics of poly(hydroxyethyl-l-asparagine)- coated liposomes is superior over that of PEG-coated liposomes at low lipid dose and upon repeated administration. Biochim Biophys Acta, 2007. 1768(3): p. 737-43.
83. Cheema, S. K., et al., Silk fibroin mediated delivery of liposomal emodin to breast cancer cells. Int J Pharm, 2007. 341(1-2): p. 221-9.
84. Liu, N. and H. J. Park, Chitosan-coated nanoliposome as vitamin E carrier. J Microencapsul, 2009. 26(3): p. 235-42.
85. Diebold, Y., et al., Ocular drug delivery by liposome-chitosan nanoparticle complexes (LCS-NP). Biomaterials, 2007. 28(8): p. 1553-64.
86. Li, N., et al., Liposome coated with low molecular weight chitosan and its potential use in ocular drug delivery. Int J Pharm, 2009. 379(1): p. 131-8.
87. Fujimoto, K., T. Toyoda, and Y. Fukui, Preparation of bionanocapsules by the layer-by-layer deposition of polypeptides onto a liposome. Macromolecules, 2007. 40(14): p. 5122-5128.
88. Fukui, Y. and K. Fujimoto, The preparation of sugar polymer-coated nano-capsules by the layer-by-layer deposition on the liposome. Langmuir, 2009. 25(17): p. 10020-5.
89. Furumoto, K., et al., Effect of coupling of albumin onto surface of PEG liposome on its in vivo disposition. Int J Pharm, 2007. 329(1-2): p. 110-6.
90. Shehata, T., et al., Prolongation of residence time of liposome by surface-modification with mixture of hydrophilic polymers. Int J Pharm, 2008. 359(1-2): p. 272-9.
91. Yokoe, J., et al., Albumin-conjugated PEG liposome enhances tumor distribution of liposomal doxorubicin in rats. Int J Pharm, 2008. 353(1-2): p. 28-34.
92. Bellavance, M. A., M. B. Poirier, and D. Fortin, Uptake and intracellular release kinetics of liposome formulations in glioma cells. Int J Pharm, 2010. 395(1-2): p. 251-9.
93. Biswas, S., et al., Development of the novel PEG-PE-based polymer for the reversible attachment of specific ligands to liposomes: synthesis and in vitro characterization. Bioconjug Chem, 2011. 22(10): p. 2005-13.
94. Boomer, J. A., et al., Cytoplasmic delivery of liposomal contents mediated by an acid-labile cholesterol-vinyl ether-PEG conjugate. Bioconjug Chem, 2009. 20(1): p. 47-59.
95. Chan, C. L., et al., Endosomal escape and transfection efficiency of PEGylated cationic liposome-DNA complexes prepared with an acid-labile PEG-lipid. Biomaterials, 2012. 33(19): p. 4928-35.
96. Hiraka, K., et al., Preparation of pH-sensitive liposomes retaining SOD mimic and their anticancer effect. Colloids Surf B Biointerfaces, 2008. 67(1): p. 54-8.
97. Ng, L. -T., E. Yuba, and K. Kono, Modification of liposome surface with pH-responsive polyampholytes for the controlled-release of drugs. Research on Chemical Intermediates, 2009. 35(8-9): p. 1015-1025.
98. Paasonen, L., et al., Temperature-sensitive poly(N-(2-hydroxypropyl)meth-acrylamide mono/dilactate)-coated liposomes for triggered contents release. Bioconjug Chem, 2007. 18(6): p. 2131-6.
99. Wehunt, M. P., et al., Controlled drug-release system based on pH-sensitive chloride-triggerable liposomes. J Liposome Res, 2013. 23(1): p. 37-46.
100. Yao, L., et al., pHLIP(R)-mediated delivery of PEGylated liposomes to cancer cells. J Control Release, 2013. 167(3): p. 228-37.
101. Romberg, B., et al., Poly(amino acid)s: promising enzymatically degradable stealth coatings for liposomes. Int J Pharm, 2007. 331(2): p. 186-9.
102. Sarkar, N., et al., Matrix metalloproteinase-assisted triggered release of liposomal contents. Bioconjug Chem, 2008. 19(1): p. 57-64.
103. Banerjee, J., et al., Release of liposomal contents by cell-secreted matrix metalloproteinase-9. Bioconjug Chem, 2009. 20(7): p. 1332-9.
104. Foged, C., H. M. Nielsen, and S. Frokjaer, Phospholipase A2 sensitive liposomes for delivery of small interfering RNA (siRNA). J Liposome Res, 2007. 17(3-4): p. 191-6.
105. Shirazi, R. S., et al., Structural evolution of environmentally responsive cationic liposome-DNA complexes with a reducible lipid linker. Langmuir, 2012. 28(28): p. 10495-503.
106. Klibanov, A. L., et al., Ultrasound-triggered release of materials entrapped in microbubble-liposome constructs: a tool for targeted drug delivery. J Control Release, 2010. 148(1): p. 13-7.
107. Dai, Z. J., et al., Sonodynamic therapy (SDT): a novel treatment of cancer based on sonosensitizer liposome as a new drug carrier. Med Hypotheses, 2013. 80(3): p. 300-2.
108. Evjen, T. J., et al., Physicochemical characterization of liposomes after ultrasound exposure - mechanisms of drug release. J Pharm Biomed Anal, 2013. 78-79: p. 118-22.
109. Ibsen, S., et al., A novel nested liposome drug delivery vehicle capable of ultrasound triggered release of its payload. J Control Release, 2011. 155(3): p. 358-66.
110. Schroeder, A., et al., Controlling liposomal drug release with low frequency ultrasound: mechanism and feasibility. Langmuir, 2007. 23(7): p. 4019-25.
111. Tinkov, S., et al., New doxorubicin-loaded phospholipid microbubbles for targeted tumor therapy: in-vivo characterization. J Control Release, 2010. 148(3): p. 368-72.
112. Schroeder, A., et al., Ultrasound triggered release of cisplatin from liposomes in murine tumors. J Control Release, 2009. 137(1): p. 63-8.
113. Suzuki, R., et al., Cancer gene therapy by IL-12 gene delivery using liposomal bubbles and tumoral ultrasound exposure. J Control Release, 2010. 142(2): p. 245-50.
114. Chen, Z., et al., Enhancement of survivin gene downregulation and cell apoptosis by a novel combination: liposome microbubbles and ultrasound exposure. Med Oncol, 2009. 26(4): p. 491-500.
115. Buchanan, K. D., et al., Encapsulation of NF-kappaB decoy oligonucleotides within echogenic liposomes and ultrasound-triggered release. J Control Release, 2010. 141(2): p. 193-8.
116. Li, L., et al., Improved intratumoral nanoparticle extravasation and penetration by mild hyperthermia. J Control Release, 2013. 167(2): p. 130-7.
117. Li, L., et al., Triggered content release from optimized stealth thermosensitive liposomes using mild hyperthermia. J Control Release, 2010. 143(2): p. 274-9.
118. Koning, G. A., et al., Hyperthermia and thermosensitive liposomes for improved delivery of chemotherapeutic drugs to solid tumors. Pharm Res, 2010. 27(8): p. 1750-4.
119. Langereis, S., et al., A Temperature-Sensitive Liposomal H-1 CEST and F-19 Contrast Agent for MR Image-Guided Drug Delivery. Journal of the American Chemical Society, 2009. 131(4): p. 1380-+.
120. Ponce, A. M., et al., Magnetic resonance imaging of temperature-sensitive liposome release: drug dose painting and antitumor effects. J Natl Cancer Inst, 2007. 99(1): p. 53-63.
121. Tai, L. A., et al., Thermosensitive liposomes entrapping iron oxide nanoparticles for controllable drug release. Nanotechnology, 2009. 20(13): p. 135101.
122. Pradhan, P., et al., Preparation and characterization of manganese ferrite-based magnetic liposomes for hyperthermia treatment of cancer. Journal of Magnetism and Magnetic Materials, 2007. 311(1): p. 208-215.
123. Clares, B., et al., Nano-engineering of 5-fluorouracil-loaded magnetolipo-somes for combined hyperthermia and chemotherapy against colon cancer. Eur J Pharm Biopharm, 2013.
124. Jo, S. -M. and J. -C. Kim, Glucose-triggered release from liposomes incorporating poly(N-isopropylacrylamide-co-methacrylic acid-co-octadecylacrylate) and glucose oxidase. Colloid and Polymer Science, 2008. 287(4): p. 379-384.
125. Yavlovich, A., et al., Design of Liposomes Containing Photopolymerizable Phospholipids for Triggered Release of Contents. J Therm Anal Calorim, 2009. 98(1): p. 97-104.
126. Komeda, C., et al., A photo-triggerable drug carrier based on cleavage of PEG lipids by photosensitiser-generated reactive singlet oxygen. Org Biomol Chem, 2013. 11(16): p. 2567-70.
127. Randles, E. G. and P. R. Bergethon, A photodependent switch of liposome stability and permeability. Langmuir, 2013. 29(5): p. 1490-7.
128. Wu, G., et al., Remotely triggered liposome release by near-infrared light absorption via hollow gold nanoshells. Journal of the American Chemical Society, 2008. 130(26): p. 8175-7.
129. Nobs, L., et al., Current methods for attaching targeting ligands to liposomes and nanoparticles. J Pharm Sci, 2004. 93(8): p. 1980-1992.
130. Torchilin, V., et al., p-Nitrophenylcarbonyl-PEG-PE-liposomes: fast and simple attachment of specific ligands, including monoclonal antibodies, to distal ends of PEG chains via p-nitrophenylcarbonyl groups. Biochimica et Biophysica Acta (BBA)-Biomembranes, 2001. 1511(2): p. 397-411.
131. Oliveira, S., et al., Downregulation of EGFR by a novel multivalent nanobody-liposome platform. J Control Release, 2010. 145(2): p. 165-75.
132. Chiu, G. N., et al., Modulation of cancer cell survival pathways using multivalent liposomal therapeutic antibody constructs. Mol Cancer Ther, 2007. 6(3): p. 844-55.
133. Hertlein, E., et al., Milatuzumab immunoliposomes induce cell death in CLL by promoting accumulation of CD74 on the surface of B cells. Blood, 2010. 116(14): p. 2554-8.
134. Etzerodt, A., et al., Efficient intracellular drug-targeting of macrophages using stealth liposomes directed to the hemoglobin scavenger receptor CD163. J Control Release, 2012. 160(1): p. 72-80.
135. Noble, C. O., et al., Characterization of highly stable liposomal and immunoliposomal formulations of vincristine and vinblastine. Cancer Chemother Pharmacol, 2009. 64(4): p. 741-51.
136. O'Donnell, R. T., et al., Development and characterization of CD22-targeted pegylated-liposomal doxorubicin (IL-PLD). Invest New Drugs, 2010. 28(3): p. 260-7.
137. Sawant, R. M., et al., Prostate cancer-specific monoclonal antibody 5D4 significantly enhances the cytotoxicity of doxorubicin-loaded liposomes against target cells in vitro. J Drug Target, 2008. 16(7): p. 601-4.
138. Elbayoumi, T. A. and V. P. Torchilin, Tumor-specific antibody-mediated targeted delivery of Doxil reduces the manifestation of auricular erythema side effect in mice. Int J Pharm, 2008. 357(1-2): p. 272-9.
139. ElBayoumi, T. A. and V. P. Torchilin, Tumor-targeted Nanomedicines: enhanced antitumor efficacy in vivo of doxorubicin-loaded, long-circulating liposomes modified with cancer-specific monoclonal antibody. Clin Cancer Res, 2009. 15(6): p. 1973-80.
140. Gupta, B. and V. P. Torchilin, Monoclonal antibody 2C5-modified doxorubicin-loaded liposomes with significantly enhanced therapeutic activity against intracranial human brain U-87 MG tumor xenografts in nude mice. Cancer Immunol Immunother, 2007. 56(8): p. 1215-23.
141. Elbayoumi, T. A., et al., Antinucleosome antibody-modified liposomes and lipid-core micelles for tumor-targeted delivery of therapeutic and diagnostic agents. J Liposome Res, 2007. 17(1): p. 1-14.
142. Rivest, V., et al., Novel liposomal formulation for targeted gene delivery. Pharm Res, 2007. 24(5): p. 981-90.
143. van der Meel, R., et al., Tumor-targeted Nanobullets: Anti-EGFR nanobodyliposomes loaded with anti-IGF-1R kinase inhibitor for cancer treatment. J Control Release, 2012. 159(2): p. 281-9.
144. Shmeeda, H., et al., Her2-targeted pegylated liposomal doxorubicin: retention of target-specific binding and cytotoxicity after in vivo passage. J Control Release, 2009. 136(2): p. 155-60.
145. Di Paolo, D., et al., Neuroblastoma-targeted nanoparticles entrapping siRNA specifically knockdown ALK. Mol Ther, 2011. 19(6): p. 1131-40.
146. Scott, R. C., et al., Targeted delivery of antibody conjugated liposomal drug carriers to rat myocardial infarction. Biotechnol Bioeng, 2007. 96(4): p. 795-802.
147. Cheng, W. W., et al., Expression and purification of two anti-CD19 single chain Fv fragments for targeting of liposomes to CD19-expressing cells. Biochem Biophys Acta, 2007. 1768(1): p. 21-9.
148. Hussain, S., et al., Antitumor activity of an epithelial cell adhesion molecule targeted nanovesicular drug delivery system. Mol Cancer Ther, 2007. 6(11): p. 3019-27.
149. Roth, A., et al., Anti-CD166 single chain antibody-mediated intracellular delivery of liposomal drugs to prostate cancer cells. Mol Cancer Ther, 2007. 6(10): p. 2737-46.
150. Sudimack, J. and R. J. Lee, Targeted drug delivery via the folate receptor. Adv Drug Deliv Rev, 2000. 41(2): p. 147-62.
151. Yang, K. K., et al., Folate-modified-chitosan-coated liposomes for tumor-targeted drug delivery. Journal of Materials Science, 2012. 48(4): p. 1717-1728.
152. Zhang, Z. and J. Yao, Preparation of irinotecan-loaded folate-targeted liposome for tumor targeting delivery and its antitumor activity. AAPS PharmSciTech, 2012. 13(3): p. 802-10.
153. Gabizon, A., et al., Improved therapeutic activity of folate-targeted liposomal doxorubicin in folate receptor-expressing tumor models. Cancer Chemother Pharmacol, 2010. 66(1): p. 43-52.
154. Yamada, A., et al., Design of folate-linked liposomal doxorubicin to its antitumor effect in mice. Clin Cancer Res, 2008. 14(24): p. 8161-8.
155. Shmeeda, H., et al., Delivery of zoledronic acid encapsulated in folate-targeted liposome results in potent in vitro cytotoxic activity on tumor cells. J Control Release, 2010. 146(1): p. 76-83.
156. Shmeeda, H., et al., Liposome encapsulation of zoledronic acid results in major changes in tissue distribution and increase in toxicity. J Control Release, 2013. 167(3): p. 265-75.
157. Moret, F., D. Scheglmann, and E. Reddi, Folate-targeted PEGylated liposomes improve the selectivity of PDT with meta-tetra(hydroxyphenyl)chlorin (m-THPC). Photochem Photobiol Sci, 2013. 12(5): p. 823-34.
158. Lu, Y., et al., Role of formulation composition in folate receptor-targeted liposomal doxorubicin delivery to acute myelogenous leukemia cells. Mol Pharm, 2007. 4(5): p. 707-12.
159. Lu, Y. and P. S. Low, Folate-mediated delivery of macromolecular anticancer therapeutic agents. Adv Drug Deliv Rev, 2002. 54(5): p. 675-93.
160. Xia, W. and P. S. Low, Folate-targeted therapies for cancer. J Med Chem, 2010. 53(19): p. 6811-24.
161. Daniels, T. R., et al., The transferrin receptor and the targeted delivery of therapeutic agents against cancer. Biochimica et Biophysica Acta (BBA)- General Subjects, 2012. 1820(3): p. 291-317.
162. Soni, V., D. V. Kohli, and S. K. Jain, Transferrin-conjugated liposomal system for improved delivery of 5-fluorouracil to brain. J Drug Target, 2008. 16(1): p. 73-8.
163. van Rooy, I., et al., Comparison of five different targeting ligands to enhance accumulation of liposomes into the brain. J Control Release, 2011. 150(1): p. 30-6.
164. Kobayashi, T., et al., Effect of transferrin receptor-targeted liposomal doxorubicin in P-glycoprotein-mediated drug resistant tumor cells. Int J Pharm, 2007. 329(1-2): p. 94-102.
165. Koshkaryev, A., A. Piroyan, and V. P. Torchilin, Increased apoptosis in cancer cells in vitro and in vivo by ceramides in transferrin-modified liposomes. Cancer Biol Ther, 2012. 13(1): p. 50-60.
166. Suzuki, R., et al., Effective anti-tumor activity of oxaliplatin encapsulated in transferrin-PEG-liposome. Int J Pharm, 2008. 346(1-2): p. 143-50.
167. Oliveira, A. C., et al., Cationic liposome-DNA complexes as gene delivery vectors: Development and behaviour towards bone-like cells. Acta Biomater, 2009. 5(6): p. 2142-51.
168. Zhang, X., et al., Transferrin receptor targeted lipopolyplexes for delivery of antisense oligonucleotide g3139 in a murine k562 xenograft model. Pharm Res, 2009. 26(6): p. 1516-24.
169. Zhong, Z. R., et al., Preparation and characterization of a novel nonviral gene transfer system: procationic-liposome-protamine-DNA complexes. Drug Deliv, 2007. 14(3): p. 177-83.
170. Mendonca, L. S., et al., Transferrin receptor-targeted liposomes encapsulating anti-BCR-ABL siRNA or asODN for chronic myeloid leukemia treatment. Bioconjug Chem, 2010. 21(1): p. 157-68.
171. Zhu, J. M., et al., Biomimetic glycoliposomes as nanocarriers for targeting P-selectin on activated platelets. Bioconjug Chem, 2007. 18(5): p. 1366-1369.
172. Chono, S., et al., Effect of surface-mannose modification on aerosolized liposomal delivery to alveolar macrophages. Drug Dev Ind Pharm, 2010. 36(1): p. 102-7.
173. Watanabe, T., et al., Liver target delivery of small interfering RNA to the HCV gene by lactosylated cationic liposome. J Hepatol, 2007. 47(6): p. 744-50.
174. Ikehara, Y., et al., Effective induction of anti-tumor immune responses with oligomannose-coated liposome targeting to intraperitoneal phagocytic cells. Cancer Lett, 2008. 260(1-2): p. 137-45.
175. Hendricks, G. L., et al., Sialylneolacto-N-tetraose c (LSTc)-bearing liposomal decoys capture influenza A virus. J Biol Chem, 2013. 288(12): p. 8061-73.
176. Higuchi, Y., et al., The potential role of fucosylated cationic liposome/ NFkappaB decoy complexes in the treatment of cytokine-related liver disease. Biomaterials, 2007. 28(3): p. 532-9.
177. Yamada, Y., et al., Postinfarct active cardiac-targeted delivery of erythropoietin by liposomes with sialyl Lewis X repairs infarcted myocardium in rabbits. Am J Physiol Heart Circ Physiol, 2013. 304(8): p. H1124-33.
178. Hirai, M., et al., Accumulation of liposome with Sialyl Lewis X to inflammation and tumor region: application to in vivo bio-imaging. Biochem Biophys Res Commun, 2007. 353(3): p. 553-8.
179. Chang, D. K., et al., A novel peptide enhances therapeutic efficacy of liposomal anti-cancer drugs in mice models of human lung cancer. PLoS One, 2009. 4(1): p. e4171.
180. Allon, N., et al., A new liposome-based gene delivery system targeting lung epithelial cells using endothelin antagonist. J Control Release, 2012. 160(2): p. 217-24.
181. Tagalakis, A. D., et al., Receptor-targeted liposome-peptide nanocomplexes for siRNA delivery. Biomaterials, 2011. 32(26): p. 6302-15.
182. Bedi, D., et al., Delivery of siRNA into breast cancer cells via phage fusion protein-targeted liposomes. Nanomedicine, 2011. 7(3): p. 315-23.
183. Jayanna, P. K., V. P. Torchilin, and V. A. Petrenko, Liposomes targeted by fusion phage proteins. Nanomedicine, 2009. 5(1): p. 83-9.
184. Shahin, M., et al., Engineered breast tumor targeting peptide ligand modified liposomal doxorubicin and the effect of peptide density on anticancer activity. Biomaterials, 2013. 34(16): p. 4089-97.
185. Shroff, K. and E. Kokkoli, PEGylated liposomal doxorubicin targeted to alpha5beta1-expressing MDA-MB-231 breast cancer cells. Langmuir, 2012. 28(10): p. 4729-36.
186. Li, C., et al., Tumor-targeted liposomal Drug Delivery mediated by a diseleno bond-stabilized cyclic peptide. Int J Nanomedicine, 2013. 8: p. 1051-62.
187. Wang, T., et al., In vitro optimization of liposomal nanocarriers prepared from breast tumor cell specific phage fusion protein. J Drug Target, 2011. 19(8): p. 597-605.
188. Koda, Y., et al., In vitro stability and permeability studies of liposomal delivery systems for a novel lipophilic endomorphin 1 analogue. Int J Pharm, 2008. 356(1-2): p. 37-43.
189. Shirakawa, M., et al., Synthesis and evaluation of a novel liposome containing BPA-peptide conjugate for BNCT. Appl Radiat Isot, 2009. 67(7-8 Suppl): p. S88-90.
190. Hulsermann, U., et al., Uptake of apolipoprotein E fragment coupled liposomes by cultured brain microvessel endothelial cells and intact brain capillaries. J Drug Target, 2009. 17(8): p. 610-8.
191. He, X., et al., A novel peptide probe for imaging and targeted delivery of liposomal doxorubicin to lung tumor. Mol Pharm, 2011. 8(2): p. 430-8.
192. Katanasaka, Y., et al., Cancer antineovascular therapy with liposome Drug Delivery systems targeted to BiP/GRP78. Int J Cancer, 2010. 127(11): p. 2685-98.
193. Rivera-Fillat, M. P., et al., Improved therapeutic responses for liposomal doxorubicin targeted via thrombospondin peptidomimetics versus untargeted doxorubicin. J Pept Sci, 2010. 16(7): p. 315-21.
194. Song, S., et al., Peptide ligand-mediated liposome distribution and targeting to EGFR expressing tumor in vivo. Int J Pharm, 2008. 363(1-2): p. 155-61.
195. Chen, X., et al., Improved tumor-targeting Drug Delivery and therapeutic efficacy by cationic liposome modified with truncated bFGF peptide. J Control Release, 2010. 145(1): p. 17-25.
196. Falciani, C., et al., Nanoparticles exposing neurotensin tumor-specific drivers. J Pept Sci, 2013. 19(4): p. 198-204.
197. Furuhata, M., et al., Decaarginine-PEG-liposome enhanced transfection efficiency and function of arginine length and PEG. Int J Pharm, 2009. 371(1-2): p. 40-6.
198. Longmuir, K. J., et al., Liposomal delivery of doxorubicin to hepatocytes in vivo by targeting heparan sulfate. Int J Pharm, 2009. 382(1-2): p. 222-33.
199. Saw, P. E., Y. T. Ko, and S. Jon, Efficient Liposomal Nanocarrier-mediated Oligodeoxynucleotide Delivery Involving Dual Use of a Cell-Penetrating Peptide as a Packaging and Intracellular Delivery Agent. Macromol Rapid Commun, 2010. 31(13): p. 1155-62.
200. Yamada, Y., et al., MITO-Porter: A liposome-based carrier system for delivery of macromolecules into mitochondria via membrane fusion. Biochim Biophys Acta, 2008. 1778(2): p. 423-32.
201. Yamada, Y. and H. Harashima, Delivery of bioactive molecules to the mitochondrial genome using a membrane-fusing, liposome-based carrier, DF-MITO-Porter. Biomaterials, 2012. 33(5): p. 1589-95.
202. Mokhtarieh, A. A., et al., Novel cell penetrating peptides with multiple motifs composed of RGD and its analogs. Biochem Biophys Res Commun, 2013. 432(2): p. 359-64.
203. Fens, M. H., et al., Liposomal encapsulation enhances the antitumour efficacy of the vascular disrupting agent ZD6126 in murine B16. F10 melanoma. Br J Cancer, 2008. 99(8): p. 1256-64.
204. Vader, P., et al., Targeted delivery of small interfering RNA to angiogenic endothelial cells with liposome-polycation-DNA particles. J Control Release, 2012. 160(2): p. 211-6.
205. Qin, Y., et al., Liposome formulated with TAT-modified cholesterol for enhancing the brain delivery. Int J Pharm, 2011. 419(1-2): p. 85-95.
206. Wang, H., et al., PEGlated magnetic polymeric liposome anchored with TAT for delivery of drugs across the Blood-spinal cord barrier. Biomaterials, 2010. 31(25): p. 6589-96.
207. Tam, Y. Y., et al., Small molecule ligands for enhanced intracellular delivery of lipid nanoparticle formulations of siRNA. Nanomedicine, 2012.
208. Anada, T., et al., Synthesis of calcium phosphate-binding liposome for Drug Delivery. Bioorg Med Chem Lett, 2009. 19(15): p. 4148-50.
209. Yamada, Y., et al., An approach to transgene expression in liver endothelial cells using a liposome-based gene vector coated with hyaluronic acid. J Pharm Sci, 2013.
210. Dalla Pozza, E., et al., Targeting gemcitabine containing liposomes to CD44 expressing pancreatic adenocarcinoma cells causes an increase in the antitumoral activity. Biochim Biophys Acta, 2013. 1828(5): p. 1396-404.
211. Madhankumar, A. B., et al., Efficacy of interleukin-13 receptor-targeted liposomal doxorubicin in the intracranial brain tumor model. Mol Cancer Ther, 2009. 8(3): p. 648-54.
212. Ichikawa, K., et al., Suppression of immune response by antigen-modified liposomes encapsulating model agents: a novel strategy for the treatment of allergy. J Control Release, 2013. 167(3): p. 284-9.
213. Murata, M., et al., Surface modification of liposomes using polymer-wheat germ agglutinin conjugates to improve the absorption of peptide drugs by pulmonary administration. J Pharm Sci, 2013. 102(4): p. 1281-9.
214. Biswas, S., et al., Liposomes loaded with paclitaxel and modified with novel triphenylphosphonium-PEG-PE conjugate possess low toxicity, target mitochondria and demonstrate enhanced antitumor effects in vitro and in vivo. J Control Release, 2012. 159(3): p. 393-402.
215. Patel, N. R., et al., Mitochondria-targeted liposomes improve the apoptotic and cytotoxic action of sclareol. J Liposome Res, 2010. 20(3): p. 244-9.
216. Koshkaryev, A., et al., Targeting of lysosomes by liposomes modified with octadecyl-rhodamine B. J Drug Target, 2011. 19(8): p. 606-14.
217. Brandwijk, R. J., et al., Anginex-conjugated liposomes for targeting of angiogenic endothelial cells. Bioconjug Chem, 2007. 18(3): p. 785-90.
218. Han, S. Y., et al., Gene transfer using liposome-complexed adenovirus seems to overcome limitations due to coxsackievirus and adenovirus receptor-deficiency of cancer cells, both in vitro and in vivo. Exp Mol Med, 2008. 40(4): p. 427-34.
219. Meng, S., et al., Enhanced antitumor effect of novel dual-targeted paclitaxel liposomes. Nanotechnology, 2010. 21(41): p. 415103.
220. Murase, Y., et al., A novel DDS strategy, "dual-targeting", and its application for antineovascular therapy. Cancer Lett, 2010. 287(2): p. 165-71.
221. Saul, J. M., A. V. Annapragada, and R. V. Bellamkonda, A dual-ligand approach for enhancing targeting selectivity of therapeutic nanocarriers. J Control Release, 2006. 114(3): p. 277-87.
222. Takara, K., et al., Size-controlled, dual-ligand modified liposomes that target the tumor vasculature show promise for use in drug-resistant cancer therapy. J Control Release, 2012. 162(1): p. 225-32.
223. Takara, K., et al., Design of a dual-ligand system using a specific ligand and cell penetrating peptide, resulting in a synergistic effect on selectivity and cellular uptake. Int J Pharm, 2010. 396(1-2): p. 143-8.
224. Chen, C. -H., et al., Evaluation of Multi-Target and Single-Target Liposomal Drugs for the Treatment of Gastric Cancer. Bioscience, Biotechnology, and Biochemistry, 2008. 72(6): p. 1586-1594.
225. Ma, K., et al., Development of a successive targeting liposome with multiligand for efficient targeting gene delivery. J Gene Med, 2011. 13(5): p. 290-301.
226. Gao, J. Q., et al., Glioma targeting and Blood-brain barrier penetration by dual-targeting doxorubincin liposomes. Biomaterials, 2013. 34(22): p. 5628-39.
227. Ying, X., et al., Dual-targeting daunorubicin liposomes improve the therapeutic efficacy of brain glioma in animals. J Control Release, 2010. 141(2): p. 183-92.
228. Jiang, T., et al., Dual-functional liposomes based on pH-responsive cellpenetrating peptide and hyaluronic acid for tumor-targeted anticancer Drug Delivery. Biomaterials, 2012. 33(36): p. 9246-58.
229. Kibria, G., et al., Dual-ligand modification of PEGylated liposomes shows better cell selectivity and efficient gene delivery. J Control Release, 2011. 153(2): p. 141-8.
230. Kluza, E., et al., Synergistic targeting of alphavbeta3 integrin and galectin-1 with heteromultivalent paramagnetic liposomes for combined MR imaging and treatment of angiogenesis. Nano Lett, 2010. 10(1): p. 52-8.
231. Kluza, E., et al., Dual-targeting of alphavbeta3 and galectin-1 improves the specificity of paramagnetic/fluorescent liposomes to tumor endothelium in vivo. J Control Release, 2012. 158(2): p. 207-14.
232. Ko, Y. T., et al., Gene delivery into ischemic myocardium by double-targeted lipoplexes with anti-myosin antibody and TAT peptide. Gene Ther, 2009. 16(1): p. 52-9.
233. Kwong, B., et al., Localized immunotherapy via liposome-anchored Anti-CD137 + IL-2 prevents lethal toxicity and elicits local and systemic antitumor immunity. Cancer Res, 2013. 73(5): p. 1547-58.
234. Laginha, K., D. Mumbengegwi, and T. Allen, Liposomes targeted via two different antibodies: assay, B-cell binding and cytotoxicity. Biochim Biophys Acta, 2005. 1711(1): p. 25-32.
235. Yu, B., et al., Targeted Drug Delivery and cross-linking induced apoptosis with anti-CD37 based dual-ligand immunoliposomes in B chronic lymphocytic leukemia cells. Biomaterials, 2013. 34(26): p. 6185-93.
236. Torchilin, V. P., Multifunctional nanocarriers. Advanced Drug Delivery Reviews, 2006. 58(14): p. 1532-1555.
237. Hansen, M. B., et al., Constrained and UV-activatable cell-penetrating peptides for intracellular delivery of liposomes. J Control Release, 2012. 164(1): p. 87-94.
238. Kale, A. A. and V. P. Torchilin, "Smart" drug carriers: PEGylated TATpmodified pH-sensitive liposomes. J Liposome Res, 2007. 17(3-4): p. 197-203.
239. Kale, A. A. and V. P. Torchilin, Enhanced transfection of tumor cells in vivo using "Smart" pH-sensitive TAT-modified pegylated liposomes. J Drug Target, 2007. 15(7-8): p. 538-45.
240. Schafer, J., et al., Liposome-polyethylenimine complexes for enhanced DNA and siRNA delivery. Biomaterials, 2010. 31(26): p. 6892-900.
241. Adil, M., et al., PR_b functionalized stealth liposomes for targeted delivery to metastatic colon cancer. Biomaterials Science, 2013. 1(4): p. 393.
242. Ko, Y. T., R. Bhattacharya, and U. Bickel, Liposome encapsulated polyethylenimine/ODN polyplexes for brain targeting. J Control Release, 2009. 133(3): p. 230-7.
243. Rothdiener, M., et al., Targeted delivery of SiRNA to CD33-positive tumor cells with liposomal carrier systems. J Control Release, 2010. 144(2): p. 251-8.
244. Movassaghian, S., et al., Dendrosome-dendriplex inside liposomes: as a gene delivery system. J Drug Target, 2011. 19(10): p. 925-932.
245. Koshkaryev, A., A. Piroyan, and V. P. Torchilin, Bleomycin in octaarginine-modified fusogenic liposomes results in improved tumor growth inhibition. Cancer Lett, 2013. 334(2): p. 293-301.
246. Negishi, Y., et al., Enhanced laminin-derived peptide AG73-mediated liposomal gene transfer by bubble liposomes and ultrasound. Mol Pharm, 2010. 7(1): p. 217-26.
247. Negussie, A. H., et al., Synthesis and in vitro evaluation of cyclic NGR peptide targeted thermally sensitive liposome. J Control Release, 2010. 143(2): p. 265-73.
248. Puri, A., et al., HER2-specific affibody-conjugated thermosensitive liposomes (Affisomes) for improved delivery of anticancer agents. J Liposome Res, 2008. 18(4): p. 293-307.
249. Karve, S., et al., The use of pH-triggered leaky heterogeneities on rigid lipid bilayers to improve intracellular trafficking and therapeutic potential of targeted liposomal immunochemotherapy. Biomaterials, 2009. 30(30): p. 6055-64.
250. Kim, M. J., et al., Preparation of pH-sensitive, long-circulating and EGFR-targeted immunoliposomes. Arch Pharm Res, 2008. 31(4): p. 539-46.
251. Koren, E., et al., Multifunctional PEGylated 2C5-immunoliposomes containing pH-sensitive bonds and TAT peptide for enhanced tumor cell internalization and cytotoxicity. J Control Release, 2012. 160(2): p. 264-73.
252. Zhu, L., P. Kate, and V. P. Torchilin, Matrix metalloprotease 2-responsive multifunctional liposomal nanocarrier for enhanced tumor targeting. ACS Nano, 2012. 6(4): p. 3491-8.
253. Riviere, K., et al., Anti-tumor activity of liposome encapsulated fluoroorotic acid as a single agent and in combination with liposome irinotecan. J Control Release, 2011. 153(3): p. 288-96.
254. Wong, M. Y. and G. N. Chiu, Liposome formulation of co-encapsulated vincristine and quercetin enhanced antitumor activity in a trastuzumab-insensitive breast tumor xenograft model. Nanomedicine, 2011. 7(6): p. 834-40.
255. Park, J., et al., Combination delivery of TGF-beta inhibitor and IL-2 by nanoscale liposomal polymeric gels enhances tumour immunotherapy. Nat Mater, 2012. 11(10): p. 895-905.
256. Belogurov, A. A., Jr., et al., Liposome-encapsulated peptides protect against experimental allergic encephalitis. FASEB J, 2013. 27(1): p. 222-31.
257. Hattori, Y., et al., Novel irinotecan-loaded liposome using phytic acid with high therapeutic efficacy for colon tumors. J Control Release, 2009. 136(1): p. 30-7.
258. Latimer, P., et al., Aerosol delivery of liposomal formulated paclitaxel and vitamin E analog reduces murine mammary tumor burden and metastases. Exp Biol Med (Maywood), 2009. 234(10): p. 1244-52.
259. Patel, N. R., et al., Reversal of multidrug resistance by co-delivery of tariquidar (XR9576) and paclitaxel using long-circulating liposomes. Int J Pharm, 2011. 416(1): p. 296-9.
260. Liang, G. W., et al., Enhanced therapeutic effects on the multi-drug resistant human leukemia cells in vitro and xenograft in mice using the stealthy liposomal vincristine plus quinacrine. Fundam Clin Pharmacol, 2008. 22(4): p. 429-37.
261. Raju, A., M. S. Muthu, and S. S. Feng, Trastuzumab-conjugated vitamin E TPGS liposomes for sustained and targeted delivery of docetaxel. Expert Opin Drug Deliv, 2013. 10(6): p. 747-60.
262. Chen, Y., et al., Multifunctional nanoparticles delivering small interfering RNA and doxorubicin overcome drug resistance in cancer. J Biol Chem, 2010. 285(29): p. 22639-50.
263. Wang, H., et al., PLGA/polymeric liposome for targeted drug and gene codelivery. Biomaterials, 2010. 31(33): p. 8741-8.
264. Xiao, W., et al., Co-delivery of doxorubicin and plasmid by a novel FGFR-mediated cationic liposome. Int J Pharm, 2010. 393(1-2): p. 119-26.
265. Pastorino, F., et al., Increase of therapeutic effects by treating melanoma with targeted combinations of c-myc antisense and doxorubicin. J Control Release, 2008. 126(1): p. 85-94.
266. Guo, L., et al., TRAIL and doxorubicin combination enhances anti-glioblastoma effect based on passive tumor targeting of liposomes. J Control Release, 2011. 154(1): p. 93-102.
267. Sun, X., et al., Co-delivery of pEGFP-hTRAIL and paclitaxel to brain glioma mediated by an angiopep-conjugated liposome. Biomaterials, 2012. 33(3): p. 916-24.
268. Sawant, R. R., et al., Palmitoyl ascorbate-modified liposomes as nanoparticle platform for ascorbate-mediated cytotoxicity and paclitaxel co-delivery. Eur J Pharm Biopharm, 2010. 75(3): p. 321-6.
269. Sawant, R. R., et al., Palmitoyl ascorbate liposomes and free ascorbic acid: comparison of anticancer therapeutic effects upon parenteral administration. Pharm Res, 2012. 29(2): p. 375-83.
270. Zhu, L. and V. P. Torchilin, Stimulus-responsive nanopreparations for tumor targeting. Integrative Biology, 2013. 5(1): p. 96-107.
271. Preiss, M. R. and G. D. Bothun, Stimuli-responsive liposome-nanoparticle assemblies. Expert Opin Drug Deliv, 2011. 8(8): p. 1025-1040.
272. Zhang, X. -X., H. S. Eden, and X. Chen, Peptides in cancer Nanomedicine: drug carriers, targeting ligands and protease substrates. Journal of Controlled Release, 2012. 159(1): p. 2-13.
273. Kaasgaard, T. and T. L. Andresen, Liposomal cancer therapy: exploiting tumor characteristics. Expert Opin Drug Deliv, 2010. 7(2): p. 225-243.
274. Doi, Y., et al., Combination therapy of metronomic S-1 dosing with oxaliplatin-containing polyethylene glycol-coated liposome improves antitumor activity in a murine colorectal tumor model. Cancer Sci, 2010. 101(11): p. 2470-5.
275. Ferrero, J. M., et al., Second-line chemotherapy with pegylated liposomal doxorubicin and carboplatin is highly effective in patients with advanced ovarian cancer in late relapse: a GINECO phase II trial. Ann Oncol, 2007. 18(2): p. 263-8.
276. Hare, J. I., E. H. Moase, and T. M. Allen, Targeting combinations of liposomal drugs to both tumor vasculature cells and tumor cells for the treatment of HER2-positive breast cancer. J Drug Target, 2013. 21(1): p. 87-96.
277. Hu, J., et al., Liposomal honokiol, a potent anti-angiogenesis agent, in combination with radiotherapy produces a synergistic antitumor efficacy without increasing toxicity. Exp Mol Med, 2008. 40(6): p. 617-28.
278. Jeong, S. Y., et al., Enhancement of radiotherapeutic effectiveness by temperature-sensitive liposomal 1-methylxanthine. Int J Pharm, 2009. 372(1-2): p. 132-9.
279. Kudoh, K., et al., Effects of bevacizumab and pegylated liposomal doxorubicin for the patients with recurrent or refractory ovarian cancers. Gynecol Oncol, 2011. 122(2): p. 233-7.
280. Li, L., et al., Liposomal curcumin with and without oxaliplatin: effects on cell growth, apoptosis, and angiogenesis in colorectal cancer. Mol Cancer Ther, 2007. 6(4): p. 1276-82.
281. Li, N., et al., Development of targeting lonidamine liposomes that circumvent drug-resistant cancer by acting on mitochondrial signaling pathways. Biomaterials, 2013. 34(13): p. 3366-80.
282. Loi, M., et al., Combined targeting of perivascular and endothelial tumor cells enhances anti-tumor efficacy of liposomal chemotherapy in neuroblas-toma. J Control Release, 2010. 145(1): p. 66-73.
283. Lowery, A., et al., Tumor-targeted delivery of liposome-encapsulated doxo-rubicin by use of a peptide that selectively binds to irradiated tumors. J Control Release, 2011. 150(1): p. 117-24.
284. Merritt, W. M., et al., Effect of interleukin-8 gene silencing with liposome-encapsulated small interfering RNA on ovarian cancer cell growth. J Natl Cancer Inst, 2008. 100(5): p. 359-72.
285. Monk, B. J., et al., Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer. J Clin Oncol, 2010. 28(19): p. 3107-14.
286. Murayama, C., et al., Liposome-encapsulated hemoglobin ameliorates tumor hypoxia and enhances radiation therapy to suppress tumor growth in mice. Artif Organs, 2012. 36(2): p. 170-7.
287. Narayanan, N. K., et al., Liposome encapsulation of curcumin and resveratrol in combination reduces prostate cancer incidence in PTEN knockout mice. Int J Cancer, 2009. 125(1): p. 1-8.
288. Yamashita, Y., et al., Convection-enhanced delivery of a topoisomerase I inhibitor (nanoliposomal topotecan) and a topoisomerase II inhibitor (pegylated liposomal doxorubicin) in intracranial brain tumor xenografts. Neuro-Oncology, 2006. 9(1): p. 20-28.
289. Yang, F. Y., et al., Treating glioblastoma multiforme with selective high-dose liposomal doxorubicin chemotherapy induced by repeated focused ultrasound. Int J Nanomedicine, 2012. 7: p. 965-74.
290. Yang, F. Y., et al., Focused ultrasound and interleukin-4 receptor-targeted liposomal doxorubicin for enhanced targeted Drug Delivery and antitumor effect in glioblastoma multiforme. J Control Release, 2012. 160(3): p. 652-8.
291. Yang, W., et al., Combination radiofrequency (RF) ablation and IV liposomal heat shock protein suppression: reduced tumor growth and increased animal endpoint survival in a small animal tumor model. J Control Release, 2012. 160(2): p. 239-44.
292. Ye, S., et al., Cationic liposome-mediated nitric oxide synthase Gene Therapy enhances the antitumor effects of cisplatin in lung cancer. Int J Mol Med, 2013. 31(1): p. 33-42.
293. Zheng, X., et al., Ultrasound-guided intratumoral administration of collagenase-2 improved liposome drug accumulation in solid tumor xenografts. Cancer Chemother Pharmacol, 2011. 67(1): p. 173-82.